Protection against influenza infection by granulocyte-macrophage colony stimulating factor
AssigneeBoard of Regents, The University of Texas System
InventorHomayoun Shams
Life of this patent
Estimating the term…
Loading patent…
AssigneeBoard of Regents, The University of Texas System
InventorHomayoun Shams
Estimating the term…
Alveolar macrophages contribute to host defenses against influenza. Enhancing their function contributed to protection against influenza and other acute lethal pulmonary infections. Wild-type mice and Tg mice expressing GM-CSF in the lung were infected with influenza virus, and lung pathology, weight loss and mortality were measured. GM-CSF was also administered to lungs of wild-type mice that were infected with influenza virus. All Tg mice expressing GM-CSF in the lungs survived with greatly reduced weight loss and lung injury and histologic evidence of a rapid host inflammatory response that controlled infection vs. wild-type mice not expressing GM-CSF in the lungs. This resistance to influenza was abrogated by elimination of alveolar phagocytes, but not by depletion of T cells, B cells or neutrophils. Tg mice had far more alveolar macrophages than wild-type mice and were more resistant to influenza-induced apoptosis. Delivery of intranasal GM-CSF to wild-type mice also conferred influenza resistance. Therefore, GM-CSF confers resistance to influenza by enhancing innate immune mechanisms that depend on alveolar macrophages. Pulmonary delivery of GM-CSF is therefore useful for reducing the significant morbidity and mortality due to influenza virus and is similarly useful in pulmonary infection caused by other infectious viral and bacterial agents.
-5. (canceled)
The method according to claim 19, wherein said administration is by an intranasal or intrapulmonary route.
The method according to claim 19, wherein the source of said hGM-CSF is a recombinant hGM-CSF polypeptide or a functional variant thereof.
The method according to claim 19, wherein the source of said hGM-CSF is a recombinant DNA molecule that encodes a hGM-CSF polypeptide or encodes a functional variant thereof, which DNA molecule is expressed in human lung cells.
A method of protecting a subject against influenza infection, comprising administering to the lungs of a subject in need thereof an effective amount of a source of hGM-CSF, thereby protecting said subject.
Dependencies are inferred from the claim text.